A pharmaceutical formulation which comprises azelastine or a pharmaceutically acceptable salt solvate or physiologically functional derivative thereof and ciclesonide.

A pharmaceutical product or formulation which comprises azelastine or a pharmaceutically acceptable salt solvate or physiologically functional derivative thereof and a steroid or a pharmaceutically acceptable salt solvate or physiologically functional derivative thereof preferably the product or formulation being in a form suitable for nasal or ocular administration.

A pharmaceutical formulation which comprises azelastine or a pharmaceutically acceptable salt solvate or physiologically functional derivative thereof and mometasone or a pharmaceutically acceptable ester thereof. 21316061 (GHMatters) 30/11/09

The present invention provides a pharmaceutical composition for nasal administration comprising mometasone furoate and azelastine hydrochloride, wherein the pharmaceutical composition comprises thaumatin as an agent for reducing bitterness and irritation.

The present invention provides a pharmaceutical composition for nasal administration comprising mometasone furoate and azelastine hydrochloride, wherein the pharmaceutical composition comprises thaumatin as an agent for reducing bitterness and irritation.

The present invention provides a pharmaceutical composition for nasal administration comprising mometasone furoate and azelastine hydrochloride wherein the pharmaceutical composition comprises thaumatin as an agent for reducing bitterness and irritation.

The invention relates to pharmacology, and specifically to eye drops which comprise recombinant interferon, a biological and physico-chemical property stabilizer, selected from the following group: low-molecular-weight polyvinylpyrrolidone, Macrogol 400-12000 and propyleneglycol, and a stabilizer of resistance to microbe contamination, selected from the following group: Nipasol, sorbic acid and boric acid, antihistamine preparations, selected from the following group: anthazoline, azelastine, te...

The invention concerns the use of an H1- and/or H2-histamine receptor antagonist for the reduction of intracranial pressure (ICP) in particular for the prevention and treatment of elevated intracranial pressure and/or secondary ischaemia in particular caused by brain injury more in particular caused by traumatic (TBI) and non-traumatic brain injury. In particular the histamine antagonist is selected from the group of acrivastine alimemazine antazoline astemizole azatadine azelastine brompheniram...

The present invention provides pharmaceutical compositions comprising azelastine or a pharmaceutically acceptable salt or ester thereof including azelastine hydrochloride and optionally one or more additional active agents. Preferred such compositions further comprise one or more pharmaceutically acceptable carriers or excipients that reduce the amount of post-nasal drip and/or that minimize or mask the unpleasant bitter taste associated with post-nasal drip of the compositions into the oral cav...